The newly formed Ergéa is now – they maintain – ‘the UK’s leading independent Managed Equipment Services business’, covering radiology, radiotherapy, endoscopy, cardiology, and surgical theatres. Ergéa also provides vendor-independent maintenance services for endoscopy, radiology, and biomedical equipment in the UK. Althea UK’s CEO, David Rolfe, will continue as the CEO of Ergéa UK. The CEO of Medipass Healthcare, John Muolo, will continue leading the Radiotherapy MES operations of Ergéa UK as Executive Vice-President and director of Strategic Relationships.
“Combining the capabilities of Althea and Medipass Healthcare in the UK allows us to bring added value to customers by offering a broader range of solutions,” said David Rolfe. “This enhanced capability has already enabled the first new MES contract to be signed, which is a direct result of the expertise, experience, and customer relationships of the combined teams. “Our new name, Ergéa, derives from a blending of words in the Greek language, and translates as ‘working for health’. The name captures our ambition to help bring better healthcare and innovations to patients.”
Ergéa UK is part of the Ergéa Group, a leading European cancer care and diagnostic imaging services platform. In Germany and Italy, Ergéa provides diagnosis and care at its own outpatient clinics, and supports private and public hospitals through embedded clinical services and MES. The majority owner of Ergéa is DWS, an asset and infrastructure manager, on behalf of one of its European infrastructure funds.
Ergéa’s service delivery, customer support, staff, and workshop locations, will remain the same, and will not be affected by the merger.